© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 24, 2022
Catherine A. Shu, MD, spoke about the most important findings from the phase 1 CHRYSALIS-2 trial for patients with previously treated EGFR-mutant non–small cell lung cancer who are administered amivantamab plus lazertinib.